CR20220316A - Tetrahidrofuranos sustituidos como moduladores de canales de sodio - Google Patents

Tetrahidrofuranos sustituidos como moduladores de canales de sodio

Info

Publication number
CR20220316A
CR20220316A CR20220316A CR20220316A CR20220316A CR 20220316 A CR20220316 A CR 20220316A CR 20220316 A CR20220316 A CR 20220316A CR 20220316 A CR20220316 A CR 20220316A CR 20220316 A CR20220316 A CR 20220316A
Authority
CR
Costa Rica
Prior art keywords
sodium channels
modulators
substituted tetrahydrofurans
compounds
pharmaceutically acceptable
Prior art date
Application number
CR20220316A
Other languages
English (en)
Inventor
Jardi Gorka Etxebarria
Stephen Andrew Thomson
Anisa Nizarali Virani
Christopher Wray
Ewa Iwona Chudyk
Timothy Donald Neubert
Meireles Lidio Carvalho
Robert Pullin
Bhairavi Galan
Yvonne Schmidt
Dean Stamos
Steven John Durrant
Nadia Ahmad
Ruah Sara S Hadida
Dennis James Hurley
Ronald Marcellus Knegtel
Joseph Pontillo
Elizabeth Mary Beck
Sarah Skerratt
Joanne Louise Pinder
David Matthew Shaw
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CR20220316A publication Critical patent/CR20220316A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Se proporcionan compuestos y sus sales farmacéuticamente aceptables, de utilidad como inhibidores de canales de sodio. También se proporcionan composiciones farmacéuticas que comprenden los compuestos o sales farmacéuticamente aceptables y métodos de uso de los compuestos, sales farmacéuticamente aceptables y composiciones farmacéuticas en el tratamiento de diversos trastornos, incluyendo el dolor.
CR20220316A 2019-12-06 2020-12-04 Tetrahidrofuranos sustituidos como moduladores de canales de sodio CR20220316A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944869P 2019-12-06 2019-12-06
PCT/US2020/063290 WO2021113627A1 (en) 2019-12-06 2020-12-04 Substituted tetrahydrofurans as modulators of sodium channels

Publications (1)

Publication Number Publication Date
CR20220316A true CR20220316A (es) 2022-10-07

Family

ID=73854989

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220316A CR20220316A (es) 2019-12-06 2020-12-04 Tetrahidrofuranos sustituidos como moduladores de canales de sodio

Country Status (21)

Country Link
US (2) US11834441B2 (es)
EP (1) EP4069691A1 (es)
JP (1) JP2023504546A (es)
KR (1) KR20220124176A (es)
CN (1) CN114945566A (es)
AR (1) AR120680A1 (es)
AU (1) AU2020397059A1 (es)
BR (1) BR112022010924A2 (es)
CA (1) CA3164134A1 (es)
CL (1) CL2022001489A1 (es)
CO (1) CO2022008969A2 (es)
CR (1) CR20220316A (es)
DO (1) DOP2022000115A (es)
EC (1) ECSP22052564A (es)
IL (1) IL293592A (es)
JO (1) JOP20220130A1 (es)
MX (1) MX2022006865A (es)
PE (1) PE20230300A1 (es)
TW (1) TW202128675A (es)
UY (1) UY38979A (es)
WO (1) WO2021113627A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014441A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
JOP20220130A1 (ar) 2019-12-06 2023-01-30 Vertex Pharma مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
EP4346818A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
EP4347585A1 (en) * 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
UY39800A (es) 2021-06-04 2023-01-31 Vertex Pharma N–(hidroxialquil (hetero)aril) tetrahidrofuran carboxamidas como moduladores de canales de sodio
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
WO2022256702A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
US20230025025A1 (en) 2021-06-15 2023-01-26 Gruenenthal Gmbh Substituted pyrazole amides
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2024041613A1 (zh) * 2022-08-24 2024-02-29 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
WO2024046253A1 (zh) * 2022-08-28 2024-03-07 上海汇伦医药股份有限公司 一种钠通道调节剂及其应用
WO2024046409A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用

Family Cites Families (412)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844732A (en) 1985-10-24 1989-07-04 Daicel Chemical Industries Ltd. Pyridine-3-carboxamide derivatives
JPH075555B2 (ja) 1986-02-25 1995-01-25 ダイセル化学工業株式会社 ピリドン−３−カルボキサミドの製法
JPH075554B2 (ja) 1986-02-25 1995-01-25 ダイセル化学工業株式会社 ５−ブロモピリドン−３−カルボキサミド化合物の製法
KR920701167A (ko) 1989-07-07 1992-08-11 에릭 에스. 딕커 약제학적 활성 화합물
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
MY106399A (en) 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
FR2665440B1 (fr) 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
JPH05107574A (ja) 1991-03-12 1993-04-30 Mitsui Petrochem Ind Ltd 有機非線形光学材料
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
IT1254134B (it) 1992-01-16 1995-09-08 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso chimicamente modificati.
SG65570A1 (en) 1992-02-25 1999-06-22 Recordati Chem Pharm Heterobicyclic compounds
IT1254469B (it) 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
EP0664792B1 (en) 1992-10-14 2000-01-05 Merck & Co. Inc. Fibrinogen receptor antagonists
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB2300856A (en) 1995-05-16 1996-11-20 Pfizer Ltd Beta-lactam preparation
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
WO1997014419A1 (en) 1995-10-20 1997-04-24 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
EP0944387A1 (en) 1996-01-30 1999-09-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5968965A (en) 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
WO1998016186A2 (en) 1996-10-16 1998-04-23 Icn Pharmaceuticals, Inc. Monocyclic l-nucleosides, analogs and uses thereof
ES2212814T3 (es) 1996-10-31 2004-08-01 Harbor Branch Oceanographic Institution, Inc. Uso de compuestos y composiciones antiinflamatorias neurogenicas.
JPH10213820A (ja) 1997-01-31 1998-08-11 Canon Inc 液晶素子及び液晶装置
US5942508A (en) 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
WO1999020309A1 (fr) 1997-10-22 1999-04-29 Eisai Co., Ltd. Agonistes de l'acide retinoique, agents preventifs et therapeutiques des nephrites
US6150379A (en) 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
BR9914207A (pt) 1998-09-30 2001-07-03 Procter & Gamble Ceto-amidas 2-substituìdas
AU1230100A (en) 1998-10-29 2000-05-22 Merck & Co., Inc. A method of treating endometriosis
SK15522001A3 (sk) 1999-04-28 2002-06-04 Aventis Pharma Deutschland Gmbh Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
AU6903200A (en) 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
MX228790B (es) 1999-09-17 2005-06-30 Millennium Pharm Inc Inhibidores del factor xa.
CZ2002961A3 (cs) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
EA200200292A1 (ru) 1999-10-29 2002-10-31 Пфайзер Продактс Инк. Производные гигромицина
IL149177A0 (en) 1999-11-05 2002-11-10 Sod Conseils Rech Applic Novel heterocyclic compounds and their use as medicines
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
MXPA02007603A (es) 2000-03-09 2003-02-24 Aventis Pharma Gmbh Usos terapeuticos de mediadores ppar.
AU7588101A (en) 2000-07-10 2002-02-05 Aurora Biosciences Corp Ion channel assay methods
MXPA03001945A (es) 2000-09-06 2003-09-10 Neurogen Corp Tetrahidroindazoles sustituidos con arilo y su uso como ligandos para el receptor gaba-a.
JP2004519473A (ja) 2000-10-24 2004-07-02 グラクソ　グループ　リミテッド Ｈｉｖプロテアーゼ阻害剤の中間体の製造方法
JP3786203B2 (ja) 2000-11-04 2006-06-14 アベンティス・フアーマ・リミテッド 置換アルカン酸
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2002055012A2 (en) 2001-01-16 2002-07-18 Astrazeneca Ab Therapeutic heterocyclic compounds
ES2364550T3 (es) 2001-03-05 2011-09-06 E. I. Du Pont De Nemours And Company Agentes de control de plagas de invertebrados de diamidas heterocíclicas.
EP1381592A1 (en) 2001-04-13 2004-01-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused compounds
JP2003034671A (ja) 2001-05-17 2003-02-07 Nippon Nohyaku Co Ltd ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法
WO2003070912A2 (en) 2001-06-06 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
WO2003000245A1 (en) 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
MXPA04002526A (es) 2001-09-21 2004-05-31 Bristol Myers Squibb Co Compuestos que contienen lactama y sus derivados como inhibidores del factor xa.
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
SE0103648D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
AU2002344567A1 (en) 2001-11-28 2003-06-10 Daiso Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
BR0307167A (pt) 2002-01-22 2005-02-09 Du Pont Composto, método e composição de controle de pragas invertebradas
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
DE60330126D1 (de) 2002-02-14 2009-12-31 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
WO2003072099A1 (en) 2002-02-21 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US7285658B2 (en) 2002-02-28 2007-10-23 Biota, Inc. Nucleotide mimics and their prodrugs
AU2003237224A1 (en) * 2002-05-29 2003-12-19 Merck And Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
AU2003286757B2 (en) 2002-11-01 2009-06-04 Merck Sharp & Dohme Corp. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
EP1581539A4 (en) 2003-01-03 2007-09-19 Bristol Myers Squibb Co NEW TYROSINE KINASE HEMMER
ES2552247T3 (es) 2003-01-08 2015-11-26 The University Of Washington Agentes antibacterianos
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
EP1616034A4 (en) 2003-04-01 2008-12-03 Activx Biosciences Inc ACYL PHOSPHATE AND PHOSPHONATE EASTS AND PROCESSES FOR THEIR SYNTHESIS AND USE IN PROTEAM ANALYSIS
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
JP2006526656A (ja) 2003-06-03 2006-11-24 ノバルティス アクチエンゲゼルシャフト ５員ヘテロ環ベースのｐ−３８阻害剤
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
NZ545710A (en) 2003-08-08 2010-02-26 Vertex Pharma Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
BRPI0413684A (pt) 2003-08-21 2006-10-24 Univ Griffith compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
JP2007502778A (ja) 2003-08-21 2007-02-15 グリフィス ユニバーシティ 新規スルフェンアミドオキシド
EP1660511B1 (en) 2003-08-27 2010-11-03 Biota Scientific Management Pty. Ltd. Novel tricyclic nucleosides or nucleotides as therapeutic agents
EP1669348A4 (en) 2003-09-30 2009-03-11 Eisai R&D Man Co Ltd NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP4526801B2 (ja) 2003-11-13 2010-08-18 新日鐵化学株式会社 複素環化合物の製造方法
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
WO2005051393A1 (en) 2003-11-25 2005-06-09 Pfizer Products Inc. Method of treatment of atherosclerosis
CA2574600C (en) 2004-07-23 2010-08-31 Pfizer Inc. Pyridine derivatives
JP2008517584A (ja) 2004-08-16 2008-05-29 アディポジェン ファーマシューティカルズ ピーティーワイ リミテッド 代謝調節薬剤およびそのための使用
ES2327945T4 (es) 2004-09-02 2010-07-02 Vertex Pharmaceuticals Incorporated Quinazolinas utiles como moduladores de los canales ionicos.
EP1858889A1 (en) 2005-03-08 2007-11-28 Biota Scientific Management Pty. Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
WO2006113615A2 (en) 2005-04-15 2006-10-26 Sloan-Kettering Institute For Cancer Research Anti-microbial agents and uses thereof
JP2008543742A (ja) 2005-05-09 2008-12-04 バーテックス ファーマシューティカルズ インコーポレイテッド ビアリール尿素およびそのアナログの調製プロセス
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
EP1891039A1 (en) 2005-05-20 2008-02-27 Vertex Pharmaceuticals Incorporated Quinoline derivatives useful as modulators of ion channels
US7880008B2 (en) 2005-05-31 2011-02-01 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
JP2007056213A (ja) 2005-08-26 2007-03-08 Fujifilm Corp 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材
DK1954697T3 (da) 2005-10-21 2010-06-14 Glaxo Group Ltd Peri-kondenserede tricykliske forbindelser, der er anvendelige som antibakterielle midler
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
WO2007081966A2 (en) 2006-01-09 2007-07-19 University Of Southern California Small molecules for treating cancer and abnormal cell proliferation disorders
UY30118A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
EP2028936A4 (en) 2006-02-13 2014-02-26 Univ Boston COMPOSITIONS AND METHODS FOR POTENTIATING ANTIBIOTICS AND DISCOVERING DRUGS
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
US7480400B2 (en) 2006-03-16 2009-01-20 Siemens Medical Solutions Usa, Inc. Detection of fiber pathways
WO2007120647A2 (en) 2006-04-11 2007-10-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
WO2008001195A2 (en) 2006-06-27 2008-01-03 Glenmark Pharmaceuticals S.A. Novel processes for the preparation of dpp iv inhibitors
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
EP1882475A1 (en) 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
KR101555258B1 (ko) 2006-08-08 2015-09-24 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제로서 유용한 헤테로아릴 화합물
JP5244596B2 (ja) 2006-08-09 2013-07-24 株式会社アイエスティー タンパク質の検出方法及びそれに用いる蛍光色素
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
CA2663147A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
CN101541759A (zh) 2006-11-27 2009-09-23 诺瓦提斯公司 取代的二氢咪唑类及其在***中的用途
RU2452484C2 (ru) 2006-12-08 2012-06-10 Милленниум Фармасьютикалз, Инк. Стандартные лекарственные препараты и способы лечения тромбоза пероральным введением ингибитора фактора ха
WO2008133753A2 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2008094507A2 (en) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
US20080234297A1 (en) 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
CN101674833A (zh) 2007-03-20 2010-03-17 柯瑞斯公司 含有锌结合半族的Raf激酶抑制剂
WO2008135826A2 (en) 2007-05-03 2008-11-13 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
EP2167058B1 (en) 2007-06-18 2015-08-12 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities
KR20100023907A (ko) 2007-06-26 2010-03-04 사노피-아벤티스 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 구리 촉매화 합성
KR101593237B1 (ko) 2007-07-19 2016-02-12 하. 룬트벡 아크티에 셀스카브 5-원 헤테로시클릭 아미드 및 관련 화합물
JP4846769B2 (ja) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
US8367702B2 (en) 2007-09-26 2013-02-05 Astellas Pharma Inc. Quinolone derivative
CN101827832B (zh) 2007-10-08 2014-05-07 阿德维纳斯治疗私人有限公司 作为葡糖激酶活化剂的乙酰胺衍生物、其制备方法及医药应用
RU2010118467A (ru) 2007-10-11 2011-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ариламиды, пригодные в качестве ингибиторов потенциалзависимых натриевых каналов
US8519137B2 (en) 2007-10-11 2013-08-27 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
CA2701766A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
WO2009069132A2 (en) 2007-11-29 2009-06-04 Ramot At Tel Aviv University Ltd. Novel reverse transcriptase inhibitors
CN101925603B (zh) 2007-12-13 2013-12-04 沃泰克斯药物股份有限公司 囊性纤维化跨膜通道调节因子的调节剂
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2244571A4 (en) 2008-01-17 2014-02-19 Purdue Research Foundation SMALL INHIBITORY MOLECULES OF HIV PROTEASES
US20120108630A1 (en) 2008-02-12 2012-05-03 The Board Of Trustees Of The Leland Stanford Junior University Hedgehog Pathway Antagonists and Methods of Use
WO2009114470A2 (en) 2008-03-10 2009-09-17 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
JP5219583B2 (ja) 2008-03-31 2013-06-26 住友化学株式会社 組成物、光学フィルムとその製造方法、光学部材及び表示装置
JP5637982B2 (ja) 2008-04-09 2014-12-10 インフィニティー ファーマシューティカルズ， インコーポレイテッド 脂肪酸アミド加水分解酵素の阻害剤
KR20110022672A (ko) 2008-06-16 2011-03-07 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
CN104193740A (zh) 2008-07-03 2014-12-10 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
JP5443720B2 (ja) 2008-09-05 2014-03-19 住友化学株式会社 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置
KR101718406B1 (ko) 2008-09-06 2017-03-21 켐진스 코포레이션 역방향 합성 ｒｎａ용 ｒｎａ 합성-포스포라미디트, 및 리간드, 크로모포어의 용이한 도입, 및 합성 ｒｎａ 3´-말단에서의 변형에서의 적용
US8541569B2 (en) 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
BRPI0919325A2 (pt) 2008-09-18 2021-03-30 F.Hoffmann-La Roche Ag Pirrolidina-2-carboxamidas substituídas
JP5743326B2 (ja) 2008-09-29 2015-07-01 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターとしてのクロメノンアナログ
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2184273A1 (de) 2008-11-05 2010-05-12 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
WO2010060952A1 (en) 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh 6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
US20110237622A1 (en) 2008-12-10 2011-09-29 Merck Frosst Canada Ltd. Renin inhibitors
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
AU2009331669B2 (en) 2008-12-23 2015-10-15 F. Hoffmann-La Roche Ag Dihydropyridone amides as P2X7 modulators
CN102264707B (zh) 2008-12-26 2014-09-03 大日本住友制药株式会社 双环型杂环化合物
KR20100087540A (ko) 2009-01-28 2010-08-05 삼성전자주식회사 잉크젯 기록용 잉크 조성물
CN102448458B (zh) 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
ES2882797T3 (es) 2009-04-02 2021-12-02 Merck Serono Sa Inhibidores de dihidroorotato deshidrogenasa
TWI496772B (zh) 2009-04-28 2015-08-21 Universal Display Corp 具有甲基－ｄ３取代之銥錯合物
EP2459565B1 (en) 2009-05-07 2018-05-02 The Board of Trustees of The Leland Stanford Junior University Saxitoxin derivatives, methods and compositions for studying, imaging, and treating pain
MX2011012631A (es) 2009-05-27 2012-03-06 Abbott Lab Inhibidores de actividad de cinasa tipo pirimidina.
CA2763624A1 (en) 2009-05-27 2010-12-02 Abbott Laboratories Pyrimidine inhibitors of kinase activity
JP5685203B2 (ja) 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
CA2771472A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
CA2773561A1 (en) 2009-09-14 2011-03-17 Phusis Therapeutics Inc. Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
US20110124597A1 (en) 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
EA201270568A1 (ru) 2009-10-16 2012-11-30 Риб-Экс Фармасьютикалз, Инк. Антимикробные композиции и способы их получения и применения
AU2011218167B2 (en) * 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
CA2791738C (en) 2010-03-01 2020-06-09 Gtx, Inc. Aryl imidazolyl compounds for the treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
EP2569307A2 (en) 2010-05-10 2013-03-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
WO2011151619A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
US20120010235A1 (en) 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
JP2013531687A (ja) * 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
WO2012020725A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
EP2624698A4 (en) 2010-10-08 2014-10-08 Abbvie Inc Furo [3,2-D] PYRIMIDINE COMPOUNDS
GB201017315D0 (en) 2010-10-13 2010-11-24 Antoxis Ltd Compound
KR101458006B1 (ko) * 2010-10-18 2014-11-04 라퀄리아 파마 인코포레이티드 Ttx-s 차단제로서의 아릴아미드 유도체
EP2630136A1 (en) 2010-10-21 2013-08-28 Universität des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
FI20106119A0 (fi) 2010-10-27 2010-10-27 Sirtuin Valley Oy Energia-aineenvaihduntaan vaikuttava koostumus
GB201020076D0 (en) 2010-11-26 2011-01-12 Liverpool School Tropical Medicine Antimalarial compounds
CN103228652B (zh) 2010-11-29 2015-02-18 辉瑞大药厂 单环内酰胺类
WO2012082187A1 (en) 2010-12-13 2012-06-21 Neural Pathways, Llc Handheld emg stimulator device with adjustable shaft length
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
TWI574687B (zh) 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
WO2012097330A2 (en) 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
AU2012212196B2 (en) 2011-02-02 2016-10-13 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
JP2012167027A (ja) 2011-02-10 2012-09-06 Shionogi & Co Ltd Ｎｐｙｙ５受容体拮抗作用を有する縮合ヘテロ環誘導体
US10385070B2 (en) 2011-02-18 2019-08-20 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
CA2829803A1 (en) 2011-03-14 2012-09-20 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
US20120238549A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Nuclear Hormone Receptor Modulators
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
JP5866100B2 (ja) 2011-04-13 2016-02-17 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
US8629141B2 (en) 2011-05-11 2014-01-14 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
DK2713722T3 (en) 2011-05-31 2017-07-03 Celgene Int Ii Sarl Newly known GLP-1 receptor stabilizers and modulators
WO2012170371A1 (en) 2011-06-10 2012-12-13 N30 Pharmaceuticals, Llc Compounds as s-nitrosoglutathione reductase inhibitors
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013022740A2 (en) 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof
WO2013040059A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Novel imidazole amines as modulators of kinase activity
WO2013049725A2 (en) 2011-09-30 2013-04-04 Tufts University Methods of using adenosine a1 receptor activation for treating depression
MX337469B (es) 2011-10-26 2016-03-02 Pfizer Ltd Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.
CN103159738B (zh) 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用
US9403839B2 (en) 2012-01-16 2016-08-02 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
FR2985916B1 (fr) 2012-01-25 2015-12-04 Univ Bordeaux Segalen Decontamination par hydrogels d'echantillons aqueux contenant des nanoparticules
CA2861439C (en) 2012-02-03 2016-07-12 Pfizer Inc. Benzimidazole and imidazopyridine derivatives as sodium channel modulators
KR20150013435A (ko) 2012-02-08 2015-02-05 그라피니티 파머수티컬스 게엠베하 친화 크로마토그래피 ＩＶ에 의한 항체 및 Ｆｃ-융합 단백질 정제용 리간드
CN107057719A (zh) 2012-02-22 2017-08-18 默克专利股份有限公司 液晶介质
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
NZ627900A (en) 2012-03-06 2016-08-26 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
JP5798066B2 (ja) 2012-03-08 2015-10-21 富士フイルム株式会社 化合物、液晶組成物、高分子材料およびフィルム
JP5804991B2 (ja) 2012-03-19 2015-11-04 富士フイルム株式会社 光反射フィルム、自動車用フロントガラス、建材用ガラス
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
CN107540594A (zh) 2012-05-30 2018-01-05 霍夫曼-拉罗奇有限公司 取代的吡咯烷‑2‑甲酰胺
JP5867298B2 (ja) 2012-06-06 2016-02-24 Jsr株式会社 フォトレジスト組成物及びレジストパターン形成方法
WO2013188881A1 (en) 2012-06-15 2013-12-19 President And Fellows Of Harvard College Compounds, compositions and methods for treating or preventing neurodegenerative disorders
US20140005181A1 (en) 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
WO2014005125A2 (en) 2012-06-29 2014-01-03 Biotium, Inc. Fluorescent compounds and uses thereof
US9040498B2 (en) 2012-07-06 2015-05-26 Research Foundation Of The City University Of New York 1,2,3-Triazolyl purine derivatives
US9403830B2 (en) 2012-07-17 2016-08-02 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
CN104640843A (zh) 2012-07-19 2015-05-20 大日本住友制药株式会社 1-(环烷基羰基)脯氨酸衍生物
MX362346B (es) 2012-07-27 2019-01-11 Biogen Ma Inc Compuestos que son agentes moduladores de s1p y/o agentes moduladores de autotaxina.
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
WO2014020152A1 (en) 2012-08-02 2014-02-06 Graffinity Pharmaceuticals Gmbh Ligands for apheresis and immunoabsorption
ES2666353T3 (es) 2012-09-06 2018-05-04 Bristol-Myers Squibb Company Inhibidores de JAK3 de imidazopiridazina y su uso para el tratamiento de enfermedades inflamatorias y autoinmunitarias
CN104812382A (zh) 2012-09-20 2015-07-29 坦普尔大学 取代的烷基二芳基衍生物、制备方法和用途
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
FR2997851B1 (fr) 2012-11-09 2014-11-28 Oreal Composition comprenant un derive dicarbonyle et procede de lissage des cheveux a partir de cette composition
WO2014078479A2 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT)
AU2013347539B2 (en) 2012-11-16 2017-06-15 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
EP2928877B1 (en) 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
MX2015008288A (es) 2013-01-08 2016-06-02 Savira Pharmaceuticals Gmbh Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
US20140200215A1 (en) 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists
CA2898674C (en) 2013-01-29 2021-01-26 Amakem Nv Pyridine derivatives as soft rock inhibitors
US9139529B2 (en) 2013-01-31 2015-09-22 Vertex Pharmaceuticals Incorporated Substituted quinoxalines as sodium channel modulators
LT2953931T (lt) 2013-01-31 2017-07-25 Vertex Pharmaceuticals Incorporated Piridono amidai kaip natrio kanalų moduliatoriai
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
CA2898653C (en) * 2013-01-31 2021-09-28 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
WO2014130856A2 (en) 2013-02-21 2014-08-28 Wayne Rothbaum Treatment of skeletal-related disorders
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
JP2014232188A (ja) 2013-05-29 2014-12-11 コニカミノルタ株式会社 セルロースアシレートフィルム、円偏光板及び画像表示装置
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
WO2015003723A1 (en) 2013-07-12 2015-01-15 Københavns Universitet Substituted 4-proline derivatives as iglur antagonists
WO2015003991A1 (en) 2013-07-12 2015-01-15 Syngenta Participations Ag Novel microbiocides
US20160145304A1 (en) 2013-07-12 2016-05-26 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamides
ES2654393T3 (es) 2013-07-19 2018-02-13 Vertex Pharmaceuticals Incorporated Sulfonamidas como moduladores de los canales de sodio
WO2015011284A2 (en) 2013-07-25 2015-01-29 Fondazione Telethon Inhibitors of fapp2 and uses thereof
EP3041470A4 (en) 2013-09-04 2017-05-03 Board Of Regents Of the University Of Texas System Methods and compositions for selective and targeted cancer therapy
DK3043803T3 (da) 2013-09-11 2022-08-01 Univ Emory Nukleotid- og nucleosidsammensætninger og deres anvendelse
KR101628288B1 (ko) 2013-09-30 2016-06-08 주식회사 엘지화학 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체
ES2721098T3 (es) 2013-10-01 2019-07-26 Glaxosmithkline Ip Dev Ltd Compuestos para cromatografía de afinidad
EP3052479A4 (en) 2013-10-02 2017-10-25 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015054337A1 (en) 2013-10-09 2015-04-16 Emory University Heterocyclic coupling catalysts and methods related thereto
BR112016012584B1 (pt) 2013-12-03 2020-10-20 Fmc Corporation composto, composições herbicidas, misturas herbicidas e método para o controle do crescimento da vegetação indesejada
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
KR20150070027A (ko) 2013-12-16 2015-06-24 메르크 파텐트 게엠베하 액정 매질
AU2014373735B2 (en) 2013-12-30 2020-03-12 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US10106549B2 (en) 2014-04-09 2018-10-23 Siteone Therapeutics, Inc. 10′,11′-modified saxitoxins useful for the treatment of pain
WO2015162244A1 (en) 2014-04-25 2015-10-29 Basf Se N-acylamidine compounds
JP6295992B2 (ja) 2014-05-09 2018-03-20 信越化学工業株式会社 単量体の製造方法
US9701627B2 (en) 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
EP3157573A4 (en) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196118A1 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170175129A1 (en) 2014-06-19 2017-06-22 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
MX2016016666A (es) 2014-07-01 2017-08-08 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
WO2016007837A1 (en) 2014-07-11 2016-01-14 Spero Therapeutics, Inc. Carbonyl linked bicyclic heteroaryl antibiotic tolerance inhibitors
WO2016011209A1 (en) 2014-07-16 2016-01-21 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP2977374A1 (en) 2014-07-21 2016-01-27 Université de Strasbourg Molecules presenting dual emission properties
EP2985334B1 (en) 2014-08-15 2018-06-20 Merck Patent GmbH Liquid-crystalline medium
WO2016029146A1 (en) 2014-08-22 2016-02-25 University Of Washington Specific inhibitors of methionyl-trna synthetase
WO2016040449A1 (en) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
JP2016079098A (ja) 2014-10-10 2016-05-16 塩野義製薬株式会社 セフェム化合物
WO2016073633A1 (en) 2014-11-05 2016-05-12 University Of Kansas SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP)
EP3229611A2 (en) 2014-12-10 2017-10-18 Mars, Incorporated Compounds that modulate fatty acid receptor activity and pet food products containing the same
FR3030242B1 (fr) 2014-12-18 2018-01-26 L'oreal Emulsion contenant un tensioactif gemine ayant deux groupements amide gras et un filtre uv organique hydrosoluble
CN105985330A (zh) 2015-02-04 2016-10-05 苏州旺山旺水生物医药有限公司 一类杂环化合物、其制备方法和用途
JP6394430B2 (ja) 2015-02-13 2018-09-26 信越化学工業株式会社 化合物、高分子化合物、レジスト材料及びパターン形成方法
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
EP3085360A1 (en) 2015-04-20 2016-10-26 Universite De Bordeaux Lipid based nanocarrier compositions loaded with metal nanoparticles and therapeutic agent
US11040976B2 (en) 2015-04-24 2021-06-22 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof
CA2985642A1 (en) 2015-05-15 2016-11-24 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
WO2016196593A1 (en) 2015-06-02 2016-12-08 E I Du Pont De Nemours And Company Substituted cyclic amides and their use as herbicides
WO2016198908A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
CA2991261A1 (en) 2015-07-06 2017-01-12 Bayer Cropscience Aktiengesellschaft Nitrogenous heterocycles as a pesticide
MX2018000360A (es) 2015-07-10 2018-06-11 Arvinas Inc Moduladores basados en mdm2 de proteolisis y metodos de uso asociados.
CN106518766A (zh) 2015-09-11 2017-03-22 中国人民解放军军事医学科学院毒物药物研究所 新型二芳基脲类化合物,其制备方法及其医药用途
CN106518767A (zh) 2015-09-11 2017-03-22 中国人民解放军军事医学科学院毒物药物研究所 取代苯并吡唑二芳基脲类化合物,其制备方法及其医药用途
WO2017051319A1 (en) 2015-09-21 2017-03-30 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
JP2018534270A (ja) 2015-09-30 2018-11-22 サイトワン セラピューティクス， インコーポレイテッド 疼痛の治療のための１１，１３−修飾サキシトキシン
WO2017059446A1 (en) 2015-10-01 2017-04-06 Memorial Sloan-Kettering Cancer Center Anthranilyl-adenosinemonosulfamate analogs and uses thereof
US11413278B2 (en) 2015-10-08 2022-08-16 The Regents Of The University Of California Compounds and methods for promoting stress resistance
WO2017066705A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
ES2914225T3 (es) 2015-10-16 2022-06-08 Modernatx Inc Análogos de cap de ARNm con enlace de fosfato modificado
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
ES2869229T3 (es) 2015-11-27 2021-10-25 Mitsubishi Tanabe Pharma Corp Derivados de 2-(((pirrolidin-3-il)carbonil)amino)-1H-imidazol como agonistas del receptor de melanocortina 1 (MCR1) para tratar la artritis reumatoide
GB201522232D0 (en) 2015-12-16 2016-01-27 Liverpool School Tropical Medicine Combination product
KR102606339B1 (ko) 2016-03-02 2023-11-24 삼성전자주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
EP4219449A3 (en) 2016-03-16 2023-10-11 Kura Oncology, Inc. Substituted indole derivatives and methods of preparation thereof
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
CA3019380A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN105906591A (zh) 2016-04-22 2016-08-31 中国药科大学 2-氨基-γ-丁内酯类盐酸盐的合成
TWI763668B (zh) * 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
WO2017223260A1 (en) 2016-06-23 2017-12-28 Albert Einstein College Of Medicine, Inc. Pu.1 inhibitors
CN106220667B (zh) 2016-07-21 2018-10-30 北京航空航天大学 螺环有机硅化合物及其应用
WO2018045106A1 (en) 2016-08-30 2018-03-08 Ohio State Innovation Foundation Anti-fungal treatment
WO2018055235A1 (en) 2016-09-21 2018-03-29 University Of Helsinki Isoxazole-amides for treating cardiac diseases
KR102458810B1 (ko) 2016-09-28 2022-10-26 메르크 파텐트 게엠베하 중합가능 액정 물질 및 중합된 액정 필름
MX2019003425A (es) 2016-09-28 2019-08-16 Blade Therapeutics Inc Moduladores de calpainas y usos terapeuticos de los mismos.
WO2018067636A1 (en) 2016-10-04 2018-04-12 Massachusetts Institute Of Technology Compositions and methods for selective carbonylation of heterocyclic compounds
EP3553065A4 (en) 2016-12-12 2020-07-01 Hangzhou Innogate Pharma Co., Ltd. HETEROCYCLIC CONNECTION AS A SYK INHIBITOR AND / OR SYK-HDAC DOUBLE INHIBITOR
WO2018138358A1 (en) 2017-01-30 2018-08-02 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
WO2018163077A1 (en) * 2017-03-08 2018-09-13 Lupin Limited Indanyl compounds as voltage gated sodium channel modulators
CN108658974A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种内酰胺类化合物及其制备方法和用途
CN108658972A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种取代内酰胺类化合物及其制备方法和用途
EP3601291A1 (en) 2017-03-29 2020-02-05 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CN110914276A (zh) 2017-03-29 2020-03-24 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
JP2020512861A (ja) 2017-03-30 2020-04-30 ショー インダストリーズ グループ インコーポレイテッド カーペットタイル及びシステムとその製造方法
EP3600318A4 (en) 2017-03-31 2021-06-09 Epizyme, Inc. METHODS FOR USING EHMT2 INHIBITORS
JP2020100564A (ja) 2017-04-03 2020-07-02 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
US11339144B2 (en) 2017-04-10 2022-05-24 Navitor Pharmaceuticals, Inc. Heteroaryl Rheb inhibitors and uses thereof
CN108689942B (zh) 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
EA201992497A1 (ru) 2017-04-20 2020-04-22 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния МОДУЛЯТОРЫ K-Ras
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
IL270680B (en) 2017-05-16 2022-06-01 Vertex Pharma Deuterium-converted pyridone amides and their prodrugs as sodium channel modulators
CN107033149B (zh) 2017-06-12 2020-01-03 上海交通大学 一种dpp-4酶抑制剂及其制备和应用
CN111051281A (zh) 2017-06-21 2020-04-21 波涛生命科学有限公司 用于合成的化合物、组合物和方法
TW201920081A (zh) 2017-07-11 2019-06-01 美商維泰克斯製藥公司 作為鈉通道調節劑的羧醯胺
CN109320509B (zh) 2017-07-31 2022-02-08 轩竹生物科技股份有限公司 Fxr受体激动剂
CN109384712B (zh) 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
WO2019036657A1 (en) 2017-08-17 2019-02-21 Kyn Therapeutics AHR INHIBITORS AND USES THEREOF
WO2019036562A1 (en) 2017-08-18 2019-02-21 Saint Louis University ERR INVERSE AGONISTS
CN109553608B (zh) 2017-09-26 2020-12-08 北京大学 一类五元六元杂环化合物及其制备方法和***的用途
MX2020007092A (es) 2017-10-18 2020-12-09 Epizyme Inc Metodos de uso de inhibidores ehmt2 para tratar o prevenir transtornos sanguineos.
CN111343989A (zh) 2017-10-18 2020-06-26 Epizyme股份有限公司 使用ehmt2抑制剂用于免疫疗法的方法
EP3700527A4 (en) 2017-10-25 2021-03-10 Children's Medical Center Corporation PAPD5 INHIBITORS AND THEIR METHODS OF USE
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
TW201922690A (zh) 2017-11-10 2019-06-16 中央研究院 環－amp反應元素結合蛋白的抑制劑
BR112020009729A2 (pt) 2017-11-15 2020-11-03 Metabomed Ltd. inibidores de acss2 e métodos de uso dos mesmos
EP3502684A1 (en) 2017-12-22 2019-06-26 Universite De Bordeaux Method for metal ion detection in aqueous solutions using nucleolipid compounds
KR20190076339A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 신규한 2,6-나프티리딘 2-옥시드 유도체 화합물 및 이의 용도
CN111315744B (zh) 2018-01-09 2023-07-14 四川科伦博泰生物医药股份有限公司 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用
SG11202006723SA (en) 2018-02-08 2020-08-28 Enyo Pharma Non-fused thiophene derivatives and their uses
TW202002971A (zh) 2018-02-12 2020-01-16 美商維泰克斯製藥公司 治療疼痛的方法
CN112040861A (zh) 2018-04-05 2020-12-04 圣犹达医疗用品心脏病学部门有限公司 高密度电极标测导管
CN112041414A (zh) 2018-04-27 2020-12-04 默克专利股份有限公司 可聚合的液晶材料和聚合的液晶膜
KR20210005160A (ko) 2018-04-27 2021-01-13 메르크 파텐트 게엠베하 중합성 액정 물질 및 중합된 액정 필름
TW202003450A (zh) 2018-05-16 2020-01-16 美商貝利特生物有限公司 脂肪酸類似物及使用方法
TWI812739B (zh) 2018-06-21 2023-08-21 景凱生物科技股份有限公司 Nadph氧化酶抑制劑、含其的醫藥組合物、及其應用
WO2020014243A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
KR20210019581A (ko) 2018-07-09 2021-02-22 리버 인스티튜트, 아이엔씨 Nav1.8을 억제하기 위한 피리딘 카르복스아미드 화합물
WO2020025030A1 (zh) 2018-08-01 2020-02-06 上海轶诺药业有限公司 一类具有免疫调节功能的芳香化合物的制备和应用
WO2020033413A2 (en) 2018-08-07 2020-02-13 Tosk, Inc. Modulators of ras gtpase
WO2020034062A1 (en) 2018-08-13 2020-02-20 Rhodia Operations Process for the reductive amination of a carbonyl compound
WO2020034058A1 (en) 2018-08-13 2020-02-20 Rhodia Operations PROCESS FOR REDUCTIVE AMINATION OF α,β-UNSATURATED CARBONYL COMPOUND
KR20210071976A (ko) 2018-09-04 2021-06-16 마젠타 테라퓨틱스 인코포레이티드 아릴 하이드로카본 수용체 길항제 및 사용 방법
CN113164454A (zh) 2018-09-28 2021-07-23 奥克塞拉有限公司 Vap-1的抑制剂
KR102092838B1 (ko) 2018-10-02 2020-03-24 성균관대학교산학협력단 신규 퓨란계 폴리카보네이트 및 이의 제조 방법
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
TW202028183A (zh) 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
AU2019362788A1 (en) 2018-10-15 2021-04-15 Dana-Farber Cancer Institute, Inc. Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof
MA54076A (fr) 2018-11-02 2022-02-09 Merck Sharp & Dohme 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
US20220119363A1 (en) 2018-11-02 2022-04-21 Merck Sharp & Dohme Corp. 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
KR102151855B1 (ko) 2018-11-30 2020-09-03 롯데케미칼 주식회사 공액 디엔계 및 방향족 비닐계 공중합체의 제조 방법 및 이로부터 제조된 공액 디엔계 및 방향족 비닐계의 공중합체를 포함하는 타이어
WO2020118036A1 (en) 2018-12-06 2020-06-11 The Children's Medical Center Corporation Antibacterial compounds and uses thereof
US20220106265A1 (en) 2018-12-11 2022-04-07 Duke University Compositions and methods for the treatment of cancer
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
CN111434655A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
KR20210114498A (ko) 2019-01-22 2021-09-23 메르크 파텐트 게엠베하 액정 중합체 필름의 제조 방법
AU2019427489A1 (en) 2019-01-28 2021-07-22 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
WO2020160225A1 (en) 2019-01-30 2020-08-06 Ohio State Innovation Foundation ESTROGEN RECEPTOR BETA (ERβ) AGONISTS FOR THE TREATMENT OF FIBROTIC CONDITIONS
WO2020191227A1 (en) 2019-03-20 2020-09-24 Cornell University Methods for controlling prostaglandin-mediated biological processes
WO2020191501A1 (en) 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
JP2022531219A (ja) 2019-04-30 2022-07-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 反応性メソゲン
EP3966217B1 (de) 2019-05-10 2023-08-02 Wacker Chemie AG Kationische germanium(ii)-verbindungen, verfahren zu deren herstellung und deren verwendung als katalysator in der hydrosilylierung
JP2022532719A (ja) 2019-05-14 2022-07-19 メタボメッド リミテッド Ａｃｓｓ２阻害剤およびその使用方法
WO2020251974A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
EP3986888A1 (en) 2019-06-21 2022-04-27 Bayer Aktiengesellschaft Thienylhydroxyisoxazolines and derivatives thereof
WO2021001739A1 (en) 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Translational enhancers and related methods
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
EP4045032A1 (en) 2019-10-17 2022-08-24 ENYO Pharma Thiophene derivatives for use in treating portal inflammation and fibrosis
JOP20220130A1 (ar) 2019-12-06 2023-01-30 Vertex Pharma مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
CN115175668A (zh) 2019-12-20 2022-10-11 三养控股公司 具有改善的奥拉帕尼的溶解度和生物利用率的组合物
JP2023529099A (ja) 2020-05-28 2023-07-07 クルゲン（シャンハイ），インク． 修飾タンパク質およびタンパク質分解誘導薬
GB202011996D0 (en) 2020-07-31 2020-09-16 Adorx Therapeutics Ltd Antagonist compounds
US20230340329A1 (en) 2020-09-24 2023-10-26 Merck Patent Gmbh Polymerizable liquid crystal material and polymerized liquid crystal film
WO2022070048A1 (en) 2020-09-29 2022-04-07 Cadila Healthcare Limited Novel amide derivatives
US20230405008A1 (en) 2020-10-21 2023-12-21 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
UY39800A (es) 2021-06-04 2023-01-31 Vertex Pharma N–(hidroxialquil (hetero)aril) tetrahidrofuran carboxamidas como moduladores de canales de sodio

Also Published As

Publication number Publication date
UY38979A (es) 2021-07-30
DOP2022000115A (es) 2022-09-30
EP4069691A1 (en) 2022-10-12
ECSP22052564A (es) 2022-08-31
CO2022008969A2 (es) 2022-09-09
TW202128675A (zh) 2021-08-01
AR120680A1 (es) 2022-03-09
US11919887B2 (en) 2024-03-05
CL2022001489A1 (es) 2023-03-03
JOP20220130A1 (ar) 2023-01-30
CN114945566A (zh) 2022-08-26
MX2022006865A (es) 2022-07-11
BR112022010924A2 (pt) 2022-09-06
US20210198241A1 (en) 2021-07-01
US11834441B2 (en) 2023-12-05
IL293592A (en) 2022-08-01
CA3164134A1 (en) 2021-06-10
AU2020397059A1 (en) 2022-07-21
JP2023504546A (ja) 2023-02-03
PE20230300A1 (es) 2023-02-13
US20230286961A1 (en) 2023-09-14
KR20220124176A (ko) 2022-09-13
WO2021113627A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
MX2022006865A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2019013574A (es) Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.
AU2024202449A1 (en) Compounds for modulating S1P1 activity and methods of using the same
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2019013954A (es) Inhibidores covalentes de kras.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12015501661A1 (en) Pyridone amides as modulators of sodium channels
MX2015009591A (es) Amidas como moduladores de canales de sodio.
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов
WO2023205463A8 (en) Heteroaryl compounds for the treatment of pain
EA201992719A1 (ru) Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов
EA202090298A1 (ru) Способы лечения муковисцидоза